Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Malfunctioning microRNAs Linked to Development of Lupus in Mouse Models

By LabMedica International staff writers
Posted on 16 Feb 2011
Another important regulatory role has been identified for microRNA, this time in activating molecular pathways leading to development of the severe autoimmune disorder lupus.

Lupus, which affects more than five million people worldwide, is a chronic autoimmune disease of connective tissue that causes the body's immune system to become hyperactive and attack normal, healthy tissue. More...
The processes leading to development of lupus have so far not been identified.

In an effort to rectify the situation, investigators at Virginia Polytechnic Institute and State University (Blacksburg, USA) used miRNA microarray assays and RT- (real-time)-PCR to measure miRNA expressions in splenic lymphocytes from three mouse lupus models (MRL-lpr, B6-lpr, and NZB/WF1) with different genetic backgrounds. The different models were distinguished by the age at which the animals began to develop lupus (as early as three months or as late as nine months, depending on the strain).

Results published in the December 10, 2010, online edition of the journal PLoS One revealed that despite the genetic differences among the three lupus stains, a common set of dysregulated miRNAs (miR-182-96-183 cluster, miR-31, and miR-155) was present in splenocytes that differed from the miRNAs found in age-matched control mice. The association of these miRNAs with the disease was highlighted by the observation that this miRNA expression pattern became evident in NZB/WF1 mice only at the age when lupus disease was manifested.

Given that miRNAs are conserved, with regard to both evolution and function, the observation of a common lupus disease-associated miRNA expression pattern in mouse lupus models is likely to have significant pathogenic, diagnostic, and/or therapeutic implications for human lupus.

"In the short term, we want to use our better understanding of the disease to develop a tool in the form of molecular markers for early, reliable diagnosis,” said senior author Dr. S. Ansar Ahmed, professor of immunology at Virginia Polytechnic Institute and State University. "The long-term goal is to offer entirely new therapeutic approaches, such as manipulation of lupus-related miRNA, to correct pathological conditions.”

"If we can do this in a mouse model and then to cure other animals, hopefully it can one day be done in humans,” said Dr. Ahmed. "This is long-range research but modern technology is narrowing the time it takes from mouse to human — speeding translation.”

Related Links:
Virginia Polytechnic Institute and State University



Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Clinical Chemistry System
P780
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.